-
Product Insights
NewUnited Kingdom (UK) Protection Insurance – Whole of Life Assurance
United Kingdom (UK) Protection Insurance Market Report Overview The number of contracts in the UK’s individual protection market declined in 2022. The total number of contracts issued was 2.2 million. Premiums rose 0.1%, mainly led by an increase in income protection and critical illness. However, inflation and the cost-of-living crisis have caused financial constraints for many consumers, making it difficult for them to afford insurance. The United Kingdom (UK) protection insurance report analyses the market drivers, competitive landscapes, and key...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Haemophilus Influenzae [Serotype B] + Hepatitis B + Pertussis (Whole Cell) + Poliomyelitis + Tetanus) (Hexavalent) Vaccine in Tetanus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Diphtheria + Haemophilus Influenzae [Serotype B] + Hepatitis B + Pertussis (Whole Cell) + Poliomyelitis +...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Haemophilus Influenzae [Serotype B] + Hepatitis B + Pertussis (Whole Cell) + Poliomyelitis + Tetanus) (Hexavalent) Vaccine in Diphtheria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Diphtheria + Haemophilus Influenzae [Serotype B] + Hepatitis B + Pertussis (Whole Cell) + Poliomyelitis +...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – (Diphtheria + Haemophilus Influenzae [Serotype B] + Hepatitis B + Pertussis (Whole Cell) + Poliomyelitis + Tetanus) (Hexavalent) Vaccine in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Diphtheria + Haemophilus Influenzae [Serotype B] + Hepatitis B + Pertussis (Whole Cell) + Poliomyelitis +...
-
Product Insights
Whole Oceans – Bucksport Salmon Aquaculture Farm – Maine
Equip yourself with the essential tools needed to make informed and profitable decisions with our Whole Oceans - Bucksport Salmon Aquaculture Farm - Maine report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
J Square Realty Associates/ SJC Ventures – Whole Foods Market – Florida
Equip yourself with the essential tools needed to make informed and profitable decisions with our J Square Realty Associates/ SJC Ventures - Whole Foods Market - Florida report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
HHI/ Richman Group/ Whole Child – Lakeland & Laurel Intergenerational Affordable Housing – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our HHI/ Richman Group/ Whole Child - Lakeland & Laurel Intergenerational Affordable Housing - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the...
-
Analyst Opinions
United Kingdom (UK) Whole of Life Assurance Distribution Dynamics and Future Market, 2022 Update
UK Whole of Life Assurance Market Report Overview Purchasing directly through insurers has been the most used channel throughout the review period for purchasing whole of life assurance policies, that accounted for more than 50% of the purchases. The UK whole of life assurance market research report explores consumer purchasing preferences for whole of life assurance, as well as how they have changed over time. It identifies what is most influential to customers when purchasing a whole of life policy...
-
Company Profile
![]()
Whole Foods Market Inc – Company Profile
Whole Foods Market Inc (Whole Foods Market), a subsidiary of Amazon.com Inc, is a natural and organic foods supermarket chain. The company's product portfolio comprises packaged goods, bulk, frozen, dairy, meat, bakery, prepared foods, coffee, tea, beer, wine, cheese, nutritional supplements, vitamins, body care, pet foods, and household goods. Whole Foods Market offers a variety of natural and organic products including non-GMO, vegan, gluten-free, dairy-free and other special diet foods under the brands such as Whole Foods Market, 365 Everyday...
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TAK-426 in Zika Virus Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.TAK-426 in Zika Virus InfectionsDrug Details:TAK-426 is under development for the prevention of Zika virus infections....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MV-140 in Urinary Tract Infections
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MV-140 in Urinary Tract Infections Drug Details: MV-140 (Uromune) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lbvd in Meningitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LBVD in Meningitis Drug Details:LBVD is under development for the prevention of diphtheria, tetanus, pertussis (whooping...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lbvd in Hepatitis B
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LBVD in Hepatitis B Drug Details:LBVD is under development for the prevention of diphtheria, tetanus, pertussis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lbvd in Poliomyelitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LBVD in Poliomyelitis Drug Details:LBVD is under development for the prevention of diphtheria, tetanus, pertussis (whooping...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lbvd in Tetanus
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LBVD in Tetanus Drug Details:LBVD is under development for the prevention of diphtheria, tetanus, pertussis (whooping...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lbvd in Diphtheria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LBVD in Diphtheria Drug Details:LBVD is under development for the prevention of diphtheria, tetanus, pertussis (whooping...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lbvd in Pertussis (Whooping Cough)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.LBVD in Pertussis (Whooping Cough) Drug Details:LBVD is under development for the prevention of diphtheria, tetanus,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – malaria [strain NF-54] vaccine 2 in Malaria
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Malaria [Strain Nf-54] Vaccine 2 in Malaria Drug Details:Vaccine candidate (PfSPZ vaccine) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IM-01 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IM-01 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) Drug Details:IM-01 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TNM-001 in Respiratory Syncytial Virus (RSV) Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.TNM-001 in Respiratory Syncytial Virus (RSV) Infections Drug Details:TNM-001 is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.